WallStSmart

Novo Nordisk A/S (NVO)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 482% more annual revenue ($333.65B vs $57.36B). NVO leads profitability with a 33.9% profit margin vs 17.5%. NVS appears more attractively valued with a PEG of 3.81. NVO earns a higher WallStSmart Score of 59/100 (C).

NVO

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 10.0Value: 5.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.13

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 5.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NVO.

NVSSignificantly Overvalued (-56.8%)

Margin of Safety

-56.8%

Fair Value

$95.95

Current Price

$150.47

$54.52 premium

UndervaluedFair: $95.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO6 strengths · Avg: 9.8/10
P/E RatioValuation
10.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
52.0%10/10

Every $100 of equity generates 52 in profit

Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
40.1%10/10

Strong operational efficiency at 40.1%

Free Cash FlowQuality
$28.10B10/10

Generating 28.1B in free cash flow

Market CapQuality
$177.74B9/10

Large-cap with strong market position

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

NVO3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.482/10

Expensive relative to growth rate

EPS GrowthGrowth
-15.8%2/10

Earnings declined 15.8%

NVS4 concerns · Avg: 3.3/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Debt/EquityHealth
1.303/10

Elevated debt levels

PEG RatioValuation
3.812/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

NVO profiles as a mature stock while NVS is a value play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.45 — expect wider price swings.

NVO is growing revenue faster at 5.6% — sustainability is the question.

NVO generates stronger free cash flow (28.1B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (59/100 vs 48/100), backed by strong 33.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?